In conclusion, our data demonstrate that in Ang II-dependent hypertension, SGLT2 inhibitors have positive effects in counteracting the development of myocardial hypertrophy and fibrosis through mechanisms independent of their effect on glycemia. The gene discussed is AGT; the disease is cardiac hypertrophy.